BMO Capital Maintains Outperform on Disc Medicine, Lowers Price Target to $100
Disc Medicine, Inc. -0.48%
Disc Medicine, Inc. IRON | 70.14 | -0.48% |
BMO Capital analyst Evan David Seigerman maintains Disc Medicine (NASDAQ:
IRON) with a Outperform and lowers the price target from $120 to $100.